+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-01-19Number of Pages: 138

Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2015 - 2023

The global endocrine testing market has been broadly segmented on the basis of selected tests, diagnostic technologies, end-users, and geography. This report studies the current scenario as well as future market potential for endocrine testing globally. This report comprises an elaborate executive summary, which includes a market snapshot on market dynamics of various segments and sub-segments in a precise manner. Moreover, executive summary comprises waterfall diagram, which reflects the market size of various segments in descending order.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global endocrine testing market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s Five Forces analysis, and market share analysis by key players (%) operating in the endocrine testing market.

Based on test, the global endocrine testing market has been segmented into estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The market for these tests has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each type has been provided for the period from 2013 to 2023. The report on the endocrine testing market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

Based on diagnostic technology, the global endocrine testing market has been segmented into five major technologies such as: tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody, sensor, and clinical chemistry technologies. The market for these types has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each product (category) has been provided for the period from 2013 to 2023. The report on the tissue engineered skin substitutes market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

The end user segmentation elucidates the global endocrine testing market by various end users that includes hospitals, commercial laboratories, ambulatory health care centers, home based tests and physician’s offices. The market for these types has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each product (category) has been provided for the period from 2013 to 2023. The report on the endocrine testing market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global endocrine testing market has been categorized into North America, Europe, Asia Pacific, and Rest of the World. The market size and forecast for each of these regions have been provided for the period from 2013 to 2023 along with CAGR (%) for the forecast period from 2013 to 2023. The research study also incorporates the competitive scenario of major players in these regions.

A list of recommendations have been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the endocrine testing market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include F-Hoffmann La Roche, Ltd., Abbott Laboratories, DiaSorin, Agilent Technologies, Siemens Healthcare, Thermo Fisher Scientific, AB SCIEX LLC, Bio Rad Laboratories, Lab Corporation, bioMerieux, Sysmex Corporation, Ortho-clinical Diagnostics, Quest Diagnostics and Biomedical Diagnostics.

The global endocrine testing market is segmented as follows:

Global Endocrine Testing Market, by Test, 2013-2023 (USD Million)

  • Estradiol (E2) Test
  • Follicle Stimulating Hormone (FSH) Test
  • Human Chorionic Gonadotropin (hCG) Test
  • Luteinizing Hormone (LH) Test
  • Dehydroepiandrosterone sulfate (DHEAS) Test
  • Progesterone Test
  • Testosterone Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Cortisol Test
  • Insulin Test
  • Others (Gastrin, Thymosin, Secretin, etc.)

Global Endocrine Testing Market, by Diagnostic Technology, 2013 – 2023 (USD Million)

  • Tandem Mass spectrometry
  • Immunoassay (Enzyme immunoassays, Radioimmunoassays  (RIA)) Technologies
  • Monoclonal and Polyclonal Antibody Technologies
  • Sensor (Electrochemical, Biosensors, etc.) Technologies
  • Clinical Chemistry Technologies
  • Others (Liquid Chromatography + Mass Spectrometry (LC-MS)

Global Endocrine Testing Market, by End User, 2013 – 2023 (USD Million)

  • Hospitals
  • Commercial Laboratories
  • Ambulatory Care Centers
  • Home Based Tests
  • Physician Offices

Global Endocrine Testing Market, by Geography, 2013 – 2023 (USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World (RoW)


Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Endocrine Testing Market Revenue, by Diagnostic Technologies, 2014 & 2023 (Value %)
2.2 Global Endocrine Testing Market Revenue, by End-User, 2014 & 2023 (US$ Million)
2.3 Global Endocrine Testing Market Revenue, by Tests, 2014 (US$ Million)
2.4 Global Endocrine Testing Market Revenue, by Geography, 2014 & 2023 (US$ Million)
2.5 Global Endocrine Testing Market, 2014 & 2023: Market Snapshot 

Chapter 3 Industry Analysis
3.1 Introduction
3.2 Market Dynamics
      3.2.1 Drivers
              3.2.1.1 Increasing Incidence of diabetic and obese population worldwide
              3.2.1.2 Consistent rise in geriatric population Worldwide
              3.2.1.3 Technological advancements
      3.2.2 Restraints
              3.2.2.1 High cost of technology
              3.2.2.2 Lack of healthcare awareness in emerging economies
      3.2.3 Opportunity
              3.2.3.1 Investment Opportunity
      3.2.4 Endocrine Testing Market: Porter’s Five Forces Analysis
      3.2.5 Market Attractiveness Analysis – Endocrine Testing Market, by Geography, 2014
      3.2.6 Competitive Landscape 
              3.2.6.1 Global Endocrine Testing Market: Market Share, by Key Players, 2014   (%)
              3.2.6.2 At Home and Physician Office Endocrine Tests Market Revenue, by Tests, 2014 (US$ Million)

Chapter 4 Market Segmentation – By Tests
4.1 Introduction
4.2 Global Estradiol (E2) Test Market Revenue, 2013-2023 (US$ Mn)
4.3 Global Follicle Stimulating Hormone (FSH) Test Market Revenue, 2013-2023 (US$ Mn)
4.4 Global Human Chorionic Gonadotropin (hCG) Test  Market Revenue, 2013-2023 (US$ Mn)
4.5 Global Luteinizing Hormone (LH) Test Market Revenue, 2013-2023 (US$ Mn)
4.6 Global Dehydroepiandrosterone sulfate (DHEAS) Test Market Revenue, 2013-2023 (US$ Mn)
4.7 Global Progesterone Test Market Revenue, 2013-2023 (US$ Mn)
4.8 Global Testosterone Test Market Revenue, 2013-2023 (US$ Mn)
4.9 Global Thyroid Stimulating Hormone (TSH) Test Market Revenue, 2013-2023 (US$ Mn)
4.10 Global Prolactin Test Market Revenue, 2013-2023 (US$ Mn)
4.11 Global Cortisol Test Market Revenue, 2013-2023 (US$ Mn)
4.12 Global Insulin Test Market Revenue, 2013-2023 (US$ Mn)
4.13 Global Other Endocrine Tests Market Revenue, 2013-2023 (US$ Mn)

Chapter 5 Market Segmentation – By Diagnostic Technology
5.1 Global Tandem Mass Spectrometry Market Revenue, 2013-2023 (US$ Mn)
5.2 Global Immunoassay Technologies Market Revenue, 2013-2023 (US$ Mn)
5.3 Global Monoclonal and Polyclonal Antibody Technologies Market Revenue, 2013-2023 (US$ Mn)
5.4 Global Sensor Technologies Market Revenue, 2013-2023 (US$ Mn)
5.5 Global Clinical Chemistry Technologies Market Revenue, 2013-2023 (US$ Mn)
5.6 Global Others Technologies Market Revenue, 2013-2023 (US$ Mn)

Chapter 6 Market Segmentation – By End User
6.1 Global Hospitals Market Revenue, 2013-2023 (US$ Mn)
6.2 Global Commercial Laboratories Market Revenue, 2013-2023 (US$ Mn)
6.3 Global Ambulatory Care Centers Market Revenue, 2013-2023 (US$ Mn)
6.4 Global Home Based tests Market Revenue, 2013-2023 (US$ Mn)
6.5 Global Physician Offices Market Revenue, 2013-2023 (US$ Mn)

Chapter 7 Market Segmentation – By Geography
7.1 North America Market Revenue, 2013-2023 (US$ Mn)
7.2 Europe Market Revenue, 2013-2023 (US$ Mn)
7.3 Asia Pacific Market Revenue, 2013-2023 (US$ Mn)
7.4 Rest of the World Market Revenue, 2013-2023 (US$ Mn)

Chapter 8 Recommendations

Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 AB Sciex Pte. Ltd.
9.3 Agilent Technologies
9.4 Biomedical Diagnostics 
9.5 bioMerieux SA 
9.6 Bio-Rad Laboratories, Inc.
9.7 DiaSorin S.p.A.
9.8 F. Hoffmann-La Roche Ltd.
9.9 Laboratory Corporation of America Holdings (LabCorp)
9.10 Ortho-Clinical Diagnostics 
9.11 Quest Diagnostics
9.12 Siemens Healthcare GmbH (Siemens AG)
9.13 Sysmex Corporation
9.14 Thermo Fisher Scientific, Inc.

Endocrine system is made of endocrine glands and hormones that secrete hormones directly into the blood stream that are crucial for regulation of several body mechanisms such as growth, development and homeostasis. The endocrine glands such as pituitary, pineal, thyroid and secretory organs such as pancreas, hypothalamus release hormones directly into the blood stream. Tests are performed to monitor levels of endocrine hormones (such as Follicle stimulating hormone (FSH), Luteinizing Hormone (LH), estradiol, insulin and others) from biological samples. These tests aid in detection of deviation in the hormone production i.e. they help detect either hypersecretion (excess secretion) or hyposecretion (less secretion) that results in certain endocrine disorders such as infertility, menopause, thyroid dysfunction and others. Responses to stress, injury, absorption of nutrients maintenance of water and electrolyte balance and energy metabolism constitutes major areas of control and integration offered by the endocrine system. 

The global endocrine testing market is categorized in three major segments; by tests, by diagnostic technology and by end users. The test segment is further categorized into 11 major hormone tests that include estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The thyroid stimulating hormone (TSH) dominated the global endocrine testing market and would continue to dominate the market during the forecast period growing at a CAGR of 7.5%. This is attributed to high prevalence of thyroid disorders among geriatric population and also is more common in females than males with a female to male ratio of 10:1. However, insulin testing market is anticipated to be the fastest growing segment during the forecast period from 2015 to 2023, where the major reason being constant rise in diabetic and obese population across the globe.

The use of technological platforms for the analysis of several endocrine hormones is essential to ensure precise and accurate test results. The diagnostic technology segment of the endocrine testing market constitutes the analysis of five major technologies: tandem mass spectrometry, monoclonal and polyclonal antibody technologies, immunoassays, sensor, and clinical chemistry technology. The others segment includes liquid chromatography-tandem mass spectro metry (LC-MS/MS). Immunoassay segment held the largest share of diagnostic technology segment growing at a CAGR of 9.1%. Tandem mass spectrometry segment is estimated to be the fastest growing diagnostic technology segment during the forecast period. Major factors driving the growth of several diagnostic technologies include increased laboratory automation and introduction of innovative technologies for analysis. Several end users represent hospitals, commercial laboratories, ambulatory care centers, home based tests and physician offices that facilitate endocrine testing. The commercial laboratories segment held the largest market share in 2014, expanding at a CAGR of 9.3% from 2015 to 2023. While Home-based tests is expected to witness highest growth rate during the forecast period of 2015 to 2023. Increasing preference of the customers towards instant test results followed by low cost supports the growth and adoption of home based test kits over the other end users (hospitals, laboratories). 

Geographically, North America dominated the endocrine testing market in 2014 with a share of 40.6% due to factors such as timely technological upgrade and increased health care awareness among patients. Additionally, increasing incidence of diabetes and obesity and constant rise in the geriatric population creates a need and demand for effective endocrine testing products and technology and thus felicitate the market growth. Asia Pacific is projected to be the most lucrative market for endocrine testing and is expected to expand at the highest growth rate of 10.3% from 2015 to 2023. Factors propelling the growth of the endocrine testing market in Asia Pacific is increased investments by several health care manufacturers in these emerging markets (Japan, China, India, Australia, and others), and higher disposable income,. Moreover, growing medical tourism for in vitro fertility treatments at low cost in developing regions such as Asia compared to developed regions is likely to boost the growth of the endocrine testing market in the region. 

The global endocrine testing market is highly oligopolistic in nature with top five players account for around 90% of the total market. F-Hoffman La Roche Ltd. dominated the endocrine testing market in 2014 with a market share of 23.1%. Major factors attributed to its dominance are broad product portfolio and high market penetration. Abbott Laboratories secured the second market position with a share of 19.3% in 2014 offering a wide array of technological platforms. DiaSorin was followed by Agilent Technologies and Siemens Healthcare holding 16.8%, 15.4% and 13.8% shares, respectively, owing to the presence of a wide range of endocrine testing products and technologies. Other players such as Thermo Fisher Scientific, AB SCIEX LLC, Bio Rad Laboratories, Lab Corporation, bioMerieux, Sysmex Corporation, Ortho-clinical Diagnostics, Quest Diagnostics and Biomedical Diagnostics contributed 11.6% of the total market revenue in the year 2014.

 

endocrine-testing-market

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries